var data={"title":"Calcium hydroxylapatite microspheres: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calcium hydroxylapatite microspheres: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/768075?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calcium-hydroxylapatite-microspheres-patient-drug-information\" class=\"drug drug_patient\">see &quot;Calcium hydroxylapatite microspheres: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46022033\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Radiesse;</li>\n      <li>Radiesse Plus</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091180\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Cosmetic Agent, Implant;</li>\n      <li>\n        Skin and Mucous Membrane Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091224\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Facial wrinkles: </b>Subdermal: Inject as required for cosmetic result (treatment volume varies based on indication/location); repeat treatment may be administered. Use a 1:1 correction factor. Do not overcorrect (overfill) a contour deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hand augmentation:</b> Subdermal: Inject in small boluses (0.2 to 0.5 mL per bolus [maximum: 0.5 mL per bolus]) as required for cosmetic result (number of injection points varies); maximum volume per hand: 3 mL. Repeat treatment may be administered (retreatment with volumes &gt;1.6 mL/hand per treatment session may result in increased adverse events). Use a 1:1 correction factor. Do not overcorrect (overfill) a contour deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091225\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091226\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091227\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46022034\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Implant, Subdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Radiesse: (0.8 mL, 1.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Radiesse Plus: (0.8 mL, 1.5 mL) [contains lidocaine hydrochloride 0.3%]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091229\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subdermal: Do not inject into blood vessels or veins or tendons in the hand. Local or topical anesthesia may be used at the injection site. Avoid passing through scar tissue and cartilage, if possible. Insert needle at approximately a 30-degree angle to the skin. Advance the needle into the subdermis; slowly inject the implant material in linear threads while withdrawing the needle. Continue placing additional lines of material until the desired level of correction is achieved; do not overcorrect. The implant material should be completely surrounded by soft tissue without leaving globular deposits. The injected area may be massaged as needed to achieve even distribution of the implant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The needle should slide under the dermis; if significant resistance is encountered when pushing the plunger, move the needle slightly or change the injection needle. Needle jams are more common with needles smaller than 27 gauge. To help avoid needle breakage, do not attempt to straighten a bent needle; discard it and complete the procedure with a replacement needle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hand augmentation: Immediately after injection, cover injection site with sterile gauze and have patient sit on hand to warm implant while the contralateral hand is being treated. After contralateral hand is treated, cover with gauze and have patient sit on it. Remove gauze from initial hand, have patient make a fist and gently massage dorsum of hand to spread evenly; repeat with contralateral hand.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091182\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Facial wrinkles:</b> Subdermal implantation for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, and also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in patients with HIV.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hand augmentation:</b> Subdermal implantation to correct volume loss in the dorsum of the hands.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29835965\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidences based on patient's diaries on days 1 to 3 postinjection of calcium hydroxylapatite.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (29%; maximal edema may occur on days 4 to 7 and may persist for up to 4 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (19%; may persist for up to 4 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (33%; may persist up to 4 weeks), ecchymoses (14%; maximal ecchymosis may occur on days 4 to 7), pruritus (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (1% to &gt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (13%; includes muscle tenderness, numbness, contour irregularity, and skin irritation; may persist for up to 4 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports (includes long-term effects up to 3 years after treatment): Abscess, alopecia, application site reaction (exposed material, over injection, under injection, superficial injection, product displacement), bleeding at injection site, blepharoptosis, bullous pemphigoid, cold intolerance, dark circles, dizziness, double vision, eczema, facial wrinkling, flu-like symptoms, granuloma, hematoma, herpes simplex infection (including reactivation), hordeolum, hyperpigmentation (upper lip), hypersensitivity reaction, hyperventilation, inflammation, ischemia, localized blanching, nausea, nodule, pallor, paralysis, residual mass at injection site, scarring, skin blister, skin cyanosis, skin discoloration, skin necrosis, skin texture changes, tachyphylaxis, thrombosis, tingling sensation, urinary tract infection, venous obstruction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091186\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to calcium hydroxylapatite or any component of the formulation; severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies; bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radiesse Plus: Additional contraindication: Known hypersensitivity to lidocaine or anesthetics of the amide type.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091187\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Injection-site reactions: Transient injection-site reactions lasting &lt;7 days, including bruising, redness, and swelling, have been observed. Coadministration of medications that may prolong bleeding (eg, aspirin, warfarin) may cause increased bruising or bleeding; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vascular occlusion: Vascular occlusion may occur following intravascular injection, resulting in infarction or embolism and subsequent ischemia, necrosis, or scarring. Intravascular injection in the face has produced rare serious adverse events, including temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage (leading to stroke), skin necrosis, and damage to underlying facial structures. Do not use in vascular rich areas (eg, glabella, nose). Vascular occlusion of the lips, nose, or glabellar or ocular region has been reported. Discontinue use immediately if changes in vision, signs of stroke, blanching of skin, or unusual pain during or shortly after the procedure occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Disorders of the hand: Use with caution in patients with autoimmune disease affecting the hand, hand implants, Dupuytren contracture, history of hand tumor, vascular malformations, Raynaud disease, and risk for tendon rupture; has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fitzpatrick skin types IV-VI: Use with caution in patients with Fitzpatrick skin types IV-VI; may have increased risk in difficulty performing tasks following injection into the dorsum of the hand.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Herpes: Treatment may result in herpes reactivation in patients with a history of herpetic eruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; HIV: Patients with HIV should only be treated by health care providers with expertise in the correction of volume deficiencies in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin infection/inflammation: Patients with an active skin infection or inflammation in or near the treatment area should not undergo treatment until the inflammatory or infectious process has been controlled. Treatment carries a risk of infection; utilize standard aseptic precautions during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Radiesse Plus: Assess the risk versus benefit in patients with congenital methemoglobinemia, patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, and patients receiving concomitant treatment with a methemoglobin-inducing agent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Safety and efficacy has not been established in patients with severe loss of fatty tissue with visible veins and tendons. Safety in patients with increased susceptibility to keloid formation and hypertrophic scarring has not been studied. Concomitant use with epilation, ultraviolet radiation, or laser, mechanical, or chemical peeling procedures has not been studied; there is a risk of inflammation at the implant site if these concomitant procedures are performed, especially prior to complete healing of the skin. Patients should minimize strenuous activity and exposure of the treatment area to extensive sun or heat for 24 hours or until any swelling and redness has resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Hand augmentation: The effect on hand function is unknown. Avoid injection into veins or tendons; may weaken or cause tendons to rupture or cause embolization or thrombosis. Use in the dorsum of the hand may result in swelling; remove rings prior to treatment and until swelling has resolved. Adverse events may occur that last &gt;14 days. Temporary difficulty performing activities may occur with injection into the dorsum of the hand; nodules, bumps, or lumps in the dorsum of the hand may last up to 1 year. Higher volume injections are associated with increased bruising; volumes &gt;3 mL per hand in a treatment session have not been studied; retreatment with volumes greater than ~1.6 mL per hand in a treatment session may result in increased adverse events (eg, redness, pain, swelling, difficulty performing activities). Treatment for &gt;1 year has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Facial wrinkles: Contours should not be overfilled; facial wrinkles should gradually improve over several weeks following treatment. Safety and efficacy for use in the lips and periorbital area have not been established; nodules have been reported when injected into the lips. Treatment for &gt;3 years has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: Should be administered by an experienced health care provider who has appropriate training, experience, knowledge of anatomy at injection site, and knowledge of aseptic technique.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27787819\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27787816\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=101419&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091183\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Reproduction studies have not been conducted. Pregnant women and women of reproductive potential who were not using effective contraception were excluded from clinical trials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091185\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if calcium hydroxylapatite is excreted in breast milk. Lactating women were excluded from clinical trials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28091221\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Subdermal injection may decrease the depth of facial wrinkles or correct volume loss in dorsum of hands.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28186845\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Radiesse (AE, AU, CR, DO, GT, HK, HN, MX, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Radiesse (calcium hydroxylapatite) [prescribing information]. Franksville, WI: Merz North America Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Radiesse (hands) (calcium hydroxylapatite) [prescribing information]. Franksville, WI: Merz North America Inc; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Radiesse Plus (calcium hydroxylapatite) [prescribing information]. Franksville, WI: Merz North America Inc; August 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 101419 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46022033\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F28091180\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F28091224\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28091225\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28091226\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28091227\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46022034\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28091229\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28091182\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F29835965\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28091186\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28091187\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F27787819\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F27787816\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28091183\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F28091185\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28091221\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F28186845\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/101419|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calcium-hydroxylapatite-microspheres-patient-drug-information\" class=\"drug drug_patient\">Calcium hydroxylapatite microspheres: Patient drug information</a></li></ul></div></div>","javascript":null}